罗欣药业集团股份有限公司2025年度业绩预告

Core Viewpoint - The company, Luoxin Pharmaceutical Group Co., Ltd., anticipates a negative net profit for the fiscal year 2025, despite improvements in operational performance and a significant reduction in losses compared to the previous year [2][5]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an expected net profit in negative territory [1]. - The financial data related to this performance forecast has not been audited by the accounting firm, but preliminary discussions have taken place without any disagreements [2]. Group 2: Reasons for Performance Changes - The company continues to strategically focus on the pharmaceutical industry, particularly in the gastrointestinal field, with significant growth driven by its core innovative drug, Tegoprazan (brand name: Taixinzan) [3]. - The commercialization of Tegoprazan has progressed well, with new indications for "duodenal ulcers" and "eradication of Helicobacter pylori in conjunction with appropriate antibiotic therapy" added to the medical insurance directory, which is expected to enhance sales and operational efficiency [4]. Group 3: Overall Business Condition - The overall business condition for 2025 shows a positive improvement trend, with a significant reduction in losses year-on-year, primarily due to the successful commercialization of Tegoprazan and the diminishing negative impact from previous asset impairments [4]. - The company has recognized fair value losses related to financial liabilities from its investment in Shangyao Luoxin, which is a non-recurring loss, and the impact is expected to be one-time as the performance guarantee period has ended [5]. - The company has initiated procedures to dispose of loss-making businesses related to LeKang Pharmaceutical and Luoxin Anruo Weita, which will further reduce losses once completed [5].